Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q2 EPS of ($2.32), $1.01 worse than the analyst estimate of ($1.31). Revenue for the quarter came in at $33.4 million versus the consensus estimate of $33.12 million.

GUIDANCE:

Karyopharm Therapeutics sees FY2026 revenue of $130-150 million, versus the consensus of $133.7 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
• Bimegren Energy (BESS) files $100M mixed shelf
• Pentagon-Backed Oil Company Is Set to Vie for Chevron's Crown in Venezuela - WSJ